<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Anesth Pain Med</journal-id><journal-id journal-id-type="iso-abbrev">Anesth Pain Med</journal-id><journal-id journal-id-type="doi">10.5812/aapm</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>Anesthesiology and Pain Medicine</journal-title></journal-title-group><issn pub-type="ppub">2228-7523</issn><issn pub-type="epub">2228-7531</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25729661</article-id><article-id pub-id-type="pmc">4335729</article-id><article-id pub-id-type="doi">10.5812/kowsar.22287523.1845</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of Botulinum Toxin Type A for Treating Chronic Low Back Pain</article-title><alt-title alt-title-type="short">Botulinum Toxin Type A for Chronic Low Back Pain for Health</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jazayeri</surname><given-names>Seyed M.</given-names></name><xref ref-type="aff" rid="aff28311">1</xref></contrib><contrib contrib-type="author"><name><surname>Ashraf</surname><given-names>Alireza</given-names></name><xref ref-type="aff" rid="aff28311">1</xref></contrib><contrib contrib-type="author"><name><surname>Fini</surname><given-names>Habib M.</given-names></name><xref ref-type="aff" rid="aff28311">1</xref></contrib><contrib contrib-type="author"><name><surname>Karimian</surname><given-names>Hajar</given-names></name><xref ref-type="aff" rid="aff28311">1</xref><xref ref-type="corresp" rid="cor28312">*</xref></contrib><contrib contrib-type="author"><name><surname>Nasab</surname><given-names>Mohamadreza V.</given-names></name><xref ref-type="aff" rid="aff28313">2</xref></contrib></contrib-group><aff id="aff28311"><label>1</label>Department of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran</aff><aff id="aff28313"><label>2</label>Department of Physical Medicine and Rehabilitation, Shahid Sadughi University of Medical Sciences, Yazd, Iran</aff><author-notes><corresp id="cor28312"><label>*</label>Corresponding author: Hajar Karimian, Department of Physical Medicine and Rehabilitation, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Zand St., Shiraz, Iran. Tel.: +98-7112319040, Fax: +98-7112319040, E-mail: <email>h_karimian2002@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>9</month><year>2011</year></pub-date><pub-date pub-type="ppub"><season>Autumn</season><year>2011</year></pub-date><volume>1</volume><issue>2</issue><fpage>77</fpage><lpage>80</lpage><history><date date-type="received"><day>08</day><month>7</month><year>2011</year></date><date date-type="rev-recd"><day>25</day><month>8</month><year>2011</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011, ISRAPM, Published by Kowsar Corp.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Low back pain is a major cause of disability and can result in substantial morbidity
and high healthcare costs. Botulinum toxin has been used successfully to alleviate pain
for a number of conditions caused by muscle contractions or spasms.</p></sec><sec><title>Objectives:</title><p>The aim of this study was to investigate the efficacy of botulinum toxin type A
(BoNT-A; Dysport&#x000ae;, Ipsen, UK) for treating chronic low back pain (CLBP).</p></sec><sec><title>Patients and Methods:</title><p>This was a single-blind, randomized clinical trial study. Fifty patients with CLBP
received either BoNT-A (40 Ipsen units per injection) or saline in 5 sites in the
paraspinal muscles (n = 25 per group). A visual analogue system (VAS) was used to
measure pain levels at baseline and at 4 and 8 weeks post-injection. Disability was
assessed using the Oswestry low back pain disability questionnaire at baseline and at 8
weeks post-injection.</p></sec><sec><title>Results:</title><p>After 4 weeks, 76% of patients in the BoNT-A group reported pain relief compared to 20%
in the saline group (P &#x0003c; 0. 005). Additionally, greater pain relief was experienced
by patients in the BoNT-A group at 8 weeks (64% vs. 12%; P &#x0003c; 0. 001). By week 8,
significant functional improvement (a minimum two-grade improvement between baseline and
post-treatment assessments) was demonstrated in a higher number of patients receiving
BoNT-A than in the saline group (68% vs. 12% , respectively; P &#x0003c; 0. 005). Patients
experienced only minor side effects.</p></sec><sec><title>Conclusions:</title><p>BoNT-A improves CLBP with a low incidence of side effects and can be used as a
therapeutic tool in the management of these patients.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Botulinum toxin type A</kwd><kwd>Low back pain</kwd><kwd>Pain</kwd></kwd-group></article-meta></front><body><sec id="sec40216"><title>1. Background</title><p>Back pain is a widespread cause of pain and disability and results in substantial
healthcare costs worldwide (<xref rid="A1845R1" ref-type="bibr">1</xref>). According to a
report from the National Institute of Neurological Disorders and Stroke, &#x0201c;Americans
spend at least $50 billion each year on low back pain, the most common cause of job-related
disability and a leading contributor to missed work. &#x0201d; Back pain is the second most
common neurological ailment in the United States; only headache is more common (<xref rid="A1845R2" ref-type="bibr">2</xref>). Although episodes of acute low back often resolve
rapidly, they can become chronic, and approximately 30%-40% of cases result in persistent,
disabling symptoms (either continuous pain or recurrent episodes) (<xref rid="A1845R3" ref-type="bibr">3</xref>). Chronic low back pain (CLBP) impairs psychosocial, behavioral,
vocational, and avocational measures of disability in many cultures and countries (<xref rid="A1845R4" ref-type="bibr">4</xref>). CLBP can have a major detrimental effect on a
patient&#x02019;s quality of life and career since without adequate treatment, those with
chronic back pain may be unable to work or perform daily tasks (<xref rid="A1845R5" ref-type="bibr">5</xref>). Studies show that effective intervention in patients with low
back pain may reduce morbidity and healthcare costs (<xref rid="A1845R6" ref-type="bibr">6</xref>).</p><p>Chemical denervation using botulinum toxin has revolutionized treatment for
many disorders involving excessive muscle activity (<xref rid="A1845R7" ref-type="bibr">7</xref>), including movement disorders such as cervical dystonia (<xref rid="A1845R8" ref-type="bibr">8</xref>, <xref rid="A1845R9" ref-type="bibr">9</xref>), tremor (<xref rid="A1845R10" ref-type="bibr">10</xref>, <xref rid="A1845R11" ref-type="bibr">11</xref>),
cerebral palsy (<xref rid="A1845R12" ref-type="bibr">12</xref>-<xref rid="A1845R14" ref-type="bibr">14</xref>), limb spasticity following stroke (<xref rid="A1845R15" ref-type="bibr">15</xref>, <xref rid="A1845R16" ref-type="bibr">16</xref>), or multiple
sclerosis (<xref rid="A1845R17" ref-type="bibr">17</xref>-<xref rid="A1845R19" ref-type="bibr">19</xref>). Botulinum toxin injections have also been reported to be
beneficial in bringing about pain relief in a variety of conditions, including low back pain
(<xref rid="A1845R20" ref-type="bibr">20</xref>-<xref rid="A1845R24" ref-type="bibr">24</xref>).</p><p>Ney et al. reported a significant improvement in back and radicular pain
after botulinum type A toxin injection (<xref rid="A1845R24" ref-type="bibr">24</xref>); in
a study in Kuwait (63%), patients showed a remarkable recovery in visual analogue system
(VAS) and functional state after botulinum type A toxin (BoNT-A) injection at 3 sites on
either side of the lumbar paraspinal muscles (<xref rid="A1845R23" ref-type="bibr">23</xref>).</p></sec><sec id="sec40217"><title>2. Objectives</title><p>The aim of this study was to assess pain and disability reduction following local
Clostridium BoNT-A hemagglutinin complex injections in paravertebral muscles at sites of
maximum discomfort in CLBP patients. We investigated the minimal effective dose of toxin for
safe outpatient treatment.</p></sec><sec id="sec40222"><title>3. Patients and Methods</title><sec id="sec40218"><title>3. 1. Participants</title><p>A total of 50 patients with CLBP who were referred to our clinic over the course of 18
months were enrolled in this single-blind, randomized clinical trial. Patients who met the
following inclusion criteria were randomized to receive either BoNT-A (Dysport&#x000ae;;
Ipsen Ltd, Slough, UK) (n = 25) or saline (n = 25):</p><list list-type="order" id="L1"><list-item><p>CLBP for a period of at least 6 months;</p></list-item><list-item><p>Ages 18&#x02013;55 years old;</p></list-item><list-item><p>Consent to participate.</p></list-item></list><p>Exclusion criteria included the following: congenital or severe spine deformity; chronic
systemic disorder; history of allergic reaction to BoNT-A; current or planned pregnancy;
breast feeding; history of neuromuscular junction disorder; presence of motor neuron
disease; primary muscle weakness; malignancy; bleeding tendency, as well as the presence
of acute pathology; any previous injection in paravertebral muscles in a 6-month period;
and suspected secondary gain. At each session, patients were evaluated for current and
past medical history and given a physical examination.</p></sec><sec id="sec40219"><title>3. 2. Study Treatment</title><p>BoNT-A was prepared by re-constituting frozen-dried toxin with sodium chloride injection
BP to a concentration of 100 Ipsen units/mL. The solution was drawn into a 1-mL syringe
and injected through a 25-gauge needle. The needle size was adjusted according to the
patient&#x02019;s level of body fat to ensure that the study treatment was delivered to the
target injection site. Patients were given 5 injections of 40 Ipsen units each at 5
equidistant lumbosacral sites (L1 to S1) in the paraspinal muscles. Tender or trigger
points were chosen as starting points for injections in both groups. All patients were
injected by the same person once unilaterally on the side of maximum discomfort. During
the study, patients were recommended to continue previously prescribed medication at their
normal dosages.</p></sec><sec id="sec40220"><title>3. 3. Assessment Measures</title><p>The level of pain was evaluated in each patient using the VAS (<xref rid="A1845R25" ref-type="bibr">25</xref>). The degree of physical impairment and disability were
assessed using the Oswestry Low Back Pain Disability Questionnaire (OLBPQ) (<xref rid="A1845R26" ref-type="bibr">26</xref>). Both assessment measures have been shown to
be reliable measures of pain and disability in patients with low pain (<xref rid="A1845R25" ref-type="bibr">25</xref>, <xref rid="A1845R27" ref-type="bibr">27</xref>). The OLBPQ is a questionnaire designed to assess the functional ability of
patients to carry out daily living tasks. It consists of 10 subsets, including questions
regarding pain intensity, personal care, lifting, walking, sitting, standing, sleeping,
sexual activity, social life, and travel. Each subset is graded from 0 (normal) to 5 (most
affected). Significant functional improvement on the OLBPQ was defined as at least a
two-grade improvement between baseline and post-treatment assessments in 4 or more
functional subsets. Subjects completed questionnaires at baseline and at 8 weeks
post-treatment.</p><p>The VAS consisted of a 10-cm horizontal line, labeled with &#x0201c;no low back
pain&#x0201d; at one end and &#x0201c;worst low back pain&#x0201d; at the other end. Patients
were asked to mark the line at a point on the line corresponding to the level of pain they
typically experienced. The distance between the point of &#x0201c;no low back pain&#x0201d;
and the patient&#x02019;s mark was measured in centimeters and used as a numeric index of
pain severity and change in pain. A significant clinical improvement in pain relief was
defined as a 50% or greater difference in pre- and post-treatment VAS scores. VAS
assessments were recorded at baseline and at 4 and 8 weeks post-treatment.</p></sec><sec id="sec40221"><title>3. 4. Statistical Analysis</title><p>Results were analyzed by an independent data management group. SPSS software version 15
was used for statistical analysis (Cary, NC, USA). Patients were included in analysis on
the basis of intention-to-treat. The VAS score at baseline, 4 weeks, and 8 weeks was
tested using repeated measures analysis of variance (ANOVA). The normality of variables
was evaluated using Kolmogorov&#x02013;Smirnov tests. According to the normality of the
variable, the 2-sided paired and t-test (Wilcoxon signed-rank test) were used for between-
and within-group comparisons, respectively. Demographic variables were compared using
Fisher&#x02019;s exact test and t-test. Adverse event frequencies were compared using the
chi-square and Fisher&#x02019;s exact tests.</p></sec></sec><sec id="sec40227"><title>4. Results</title><sec id="sec40223"><title>4. 1. Demographic Data</title><p>All 50 patients consented and completed the study. The mean age of patients was 42 years
(range, 18&#x02013;55 years). Of the 25 patients in each group, 13 women were assigned to
the BoNT-A group and 14 women received saline. The mean duration of pain was 4 years (8
months to 9 years) and the mean pain score on the VAS was 6. 5. At baseline, functional
impairment was recorded in 4 to 10 subsets on the OLBPQ. On the basis of ANOVA results
(age, sex, and duration of pain), we concluded that there was no significant differences
between the treatment and control groups. A comparison of both groups showed no baseline
differences in VAS score and OLBPQ subsets (<xref ref-type="table" rid="tbl10569">Table
1</xref>).</p><table-wrap id="tbl10569" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Demographic Data of Patients Receiving BoNT-A or Saline</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th style="text-align: left;" rowspan="1" colspan="1">BoNT-A <xref ref-type="table-fn" rid="fn6954"><sup>a</sup></xref></th><th style="text-align: left;" rowspan="1" colspan="1">Saline</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Number of patients</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">25</td></tr><tr><td rowspan="1" colspan="1">Men:Women</td><td rowspan="1" colspan="1">12:13</td><td rowspan="1" colspan="1">11:14</td></tr><tr><td rowspan="1" colspan="1">Mean (range), y</td><td rowspan="1" colspan="1">41. 7 (21-55)</td><td rowspan="1" colspan="1">42. 3 (18-53)</td></tr><tr><td rowspan="1" colspan="1">Mean pain duration, y</td><td rowspan="1" colspan="1">4. 4</td><td rowspan="1" colspan="1">3. 6</td></tr><tr><td rowspan="1" colspan="1">Baseline VAS<xref ref-type="table-fn" rid="fn6954"><sup>a</sup></xref> score</td><td rowspan="1" colspan="1">6. 1</td><td rowspan="1" colspan="1">6. 9</td></tr></tbody></table><table-wrap-foot><fn id="fn6954"><p><sup>a</sup>Abbreviations: BoNT-A, Botulinum toxin type A; VAS, Visual analogue
system</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec40224"><title>4. 2. Pain Relief</title><p>At week 4, 19 of 25 patients (76%) who received BoNT-A showed a clinical response on the
VAS compared with 5 of 25 patients (20%) in the group receiving saline (P &#x0003c; 0. 005
BoNT-A vs. saline). At week 8, 16 of 25 patients (64%) in the BoNT-A group experienced
significant pain relief compared with 3 of 25 patients (12%) in placebo group (P &#x0003c;0.011 BoNT-A vs. saline).</p></sec><sec id="sec40225"><title>4. 3. Functional Improvement</title><p>Functional improvement was also demonstrated in patients who received BoNT-A (<xref ref-type="table" rid="tbl10570">Table 2</xref>). By week 8, 17 of 25 patients (68%) in
the BoNT-A group demonstrated clinical improvement compared with 3 of 25 patients (12%)
receiving saline (P &#x0003c; 0. 005).</p><table-wrap id="tbl10570" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Improvements in Pain and Function Disability</title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;" rowspan="1" colspan="1">Pain Relief (VAS) <xref ref-type="table-fn" rid="fn6955"><sup>a</sup></xref></th><th style="text-align: left;" rowspan="1" colspan="1">BoNT-A <sup><xref ref-type="table-fn" rid="fn6955">a</xref>, <xref ref-type="table-fn" rid="fn6956">b</xref></sup> (n = 25),
No. (%)</th><th style="text-align: left;" rowspan="1" colspan="1">Saline (n = 25), No. (%)</th><th style="text-align: left;" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td style="padding-left:25pt;" rowspan="1" colspan="1">Week 4</td><td rowspan="1" colspan="1">19 (76)</td><td rowspan="1" colspan="1">5 (20)</td><td rowspan="1" colspan="1">&#x0003c; 0. 005</td></tr><tr><td style="padding-left:25pt;" rowspan="1" colspan="1">Week 8</td><td rowspan="1" colspan="1">16 (64)</td><td rowspan="1" colspan="1">3 (12)</td><td rowspan="1" colspan="1">&#x0003c; 0. 011</td></tr><tr><td rowspan="1" colspan="1">Functional improvement (OLBPQ)
<sup><xref ref-type="table-fn" rid="fn6955">a</xref>, <xref ref-type="table-fn" rid="fn6957">c</xref></sup></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td style="padding-left:25pt;" rowspan="1" colspan="1">Week 8</td><td rowspan="1" colspan="1">17 (68)</td><td rowspan="1" colspan="1">3(12)</td><td rowspan="1" colspan="1">&#x0003c; 0. 005</td></tr></tbody></table><table-wrap-foot><fn id="fn6955"><p><sup>a</sup>Abbreviations: BoNT-A, Botulinum toxin type A; VAS, Visual analogue
system</p></fn><fn id="fn6956"><p><sup>b</sup>Defined as a 50% or greater difference in pre- and post-treatment VAS
scores</p></fn><fn id="fn6957"><p><sup>c</sup>Defined as at least a two-grade improvement between baseline and
post-treatment assessments in 4 or more functional subsets on the OLBPQ</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec40226"><title>4. 4. Safety Profile</title><p>There was no evidence of significant complications or pain exacerbation in either
group.</p></sec></sec><sec id="sec40228"><title>5. Discussion</title><p>The aim of this study was to assess pain and disability reduction following local
Clostridium botulinum type A toxin injections and placebo treatment in patients with CLBP.
</p><p>In this single-blind, placebo-controlled study, significant inter-group differences for
individual pain scores were demonstrated. Patients who received BoNT-A as a therapeutic
intervention showed a lower pain score compared to the placebo group. Furthermore, our study
showed a statistically significant difference in functional improvement in the
BoNT-A-receiving group. Treatment was safe, and no side effects were observed. Our results
are similar to those of a small, double-blind trial involving BoNT-A administration for
treating CLBP (<xref rid="A1845R21" ref-type="bibr">21</xref>). Similarly, Jabbari et al. ,
in an open label study involving 75 patients, reported a significant reduction in low back
pain after BoNT-A injection (<xref rid="A1845R28" ref-type="bibr">28</xref>). Subinetal, in
a smaller randomized trial involving 19 patients with low back pain who were followed-up at
1 and 6 months, showed improvement in McGill Scores and Oswestry and Roland-Morris scores
(<xref rid="A1845R29" ref-type="bibr">29</xref>). Ney et al. reported a significant
improvement in back and radicular pain after injection of BoNT-A (<xref rid="A1845R24" ref-type="bibr">24</xref>).</p><p>BoNT-A is a potent inhibitor of acetylcholine release as well
as a number of other neurotransmitters and neuropeptides. Botulinum toxin exerts its effects
through inhibiting excessive acetylcholine release; it also has muscle relaxant properties,
preventing stimulation of muscle nociceptors. It has also been postulated that botulinum
toxin may have an analgesic effect, although the precise mechanism of action is unknown
(<xref rid="A1845R30" ref-type="bibr">30</xref>, <xref rid="A1845R31" ref-type="bibr">31</xref>). Additionally, in vitro inhibition of substance P by BoNT-A has been reported
(<xref rid="A1845R32" ref-type="bibr">32</xref>). Our study indicates the benefits and
safety of paraspinal administration of botulinum toxin A for low back pain that has been
demonstrated in previous studies. There are a few limitations to our study. First, our study
evaluated a small number of patients. Furthermore, the extent of patient and physician bias
is unclear. Patients may have over- or underestimated the effect of the medication based on
preconceived expectations. Administration of BoNT-A to reduce muscle tone and over-activity
that has occurred through injury and inflammation should form part of an overall treatment
approach that also includes physical therapy. Ultimately, restoration of both normal muscle
length and biomechanical balance will benefit patients by improving long-term pain relief.
Further investigations of BoNT-A in chronic back pain are necessary to determine the
reproducibility of the results and the long-term effect of repeated injections.
Consideration should also be given regarding BoNT-A dose, the number and site of injections,
the necessity of follow-up injections, and the length of treatment appropriate to the
disorder. In patients with CLBP, 200 Ipsen units of BoNT-A administered at 40 Ipsen units
over 5 sites was effective in conferring pain relief and showed no side effects.</p></sec></body><back><ack><p>We would like to thank Shiraz University of Medical Sciences for supplying the study
medication and supporting this work.</p></ack><fn-group><fn id="afn22417" fn-type="other"><p><bold>Implication for health policy/practice/research/medical education:</bold>This study focused on the relation between low back pain which is a major cause of
disability, and can result in substantial morbidity and high healthcare costs, and
botulinum toxin which has been used successfully to alleviate pain in a number of
conditions caused by muscle contractions or spasms. This study can be beneficial for
Physicians, Pain managements and specialists who care about pain.</p></fn><fn id="afn22418" fn-type="other"><p><bold>Please cite this paper as:</bold>Jazayeri SM, Ashraf A, Fini HM, Karimian H, Nasab MV. Efficacy of Botulinum Toxin Type A
for Treating Chronic Low Back Pain. Anesth Pain. 2011;1(2): 77-80. DOI:
10.5812/kowsar.22287523.1845</p></fn><fn id="afn22419" fn-type="financial-disclosure"><p><bold>Financial Disclosure:</bold>None declared. </p></fn><fn id="afn22420" fn-type="supported-by"><p><bold>Funding/Support:</bold>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="A1845R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagenais</surname><given-names>S</given-names></name><name><surname>Caro</surname><given-names>J</given-names></name><name><surname>Haldeman</surname><given-names>S</given-names></name></person-group><article-title>A systematic review of low back pain cost of illness studies in the United
States and internationally.</article-title><source>Spine J.</source><year>2008</year><volume>8</volume><issue>1</issue><fpage>8</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.spinee.2007.10.005</pub-id><pub-id pub-id-type="pmid">18164449</pub-id></element-citation></ref><ref id="A1845R2"><label>2</label><element-citation publication-type="web"><article-title>National Institute of Neurological Disordersand Stroke. Low Back Pain Fact
Sheet.;</article-title><date-in-citation content-type="updated">June 15, 2011; cited 2010</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ninds.nih.gov/disorders/backpain/detail_backpain.htm">http://www.ninds.nih.gov/disorders/backpain/detail_backpain.htm</ext-link></comment></element-citation></ref><ref id="A1845R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamcan</surname><given-names>O</given-names></name><name><surname>Mannion</surname><given-names>AF</given-names></name><name><surname>Eisenring</surname><given-names>C</given-names></name><name><surname>Horisberger</surname><given-names>B</given-names></name><name><surname>Elfering</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>U</given-names></name></person-group><article-title>The course of chronic and recurrent low back pain in the general
population.</article-title><source>Pain.</source><year>2010</year><volume>150</volume><issue>3</issue><fpage>451</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2010.05.019</pub-id><pub-id pub-id-type="pmid">20591572</pub-id></element-citation></ref><ref id="A1845R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>NE</given-names></name><name><surname>Thomas</surname><given-names>E</given-names></name><name><surname>Bishop</surname><given-names>A</given-names></name><name><surname>Dunn</surname><given-names>KM</given-names></name><name><surname>Main</surname><given-names>CJ</given-names></name></person-group><article-title>Distinctiveness of psychological obstacles to recovery in low back pain
patients in primary care.</article-title><source>Pain.</source><year>2010</year><volume>148</volume><issue>3</issue><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2009.11.002</pub-id><pub-id pub-id-type="pmid">20022697</pub-id></element-citation></ref><ref id="A1845R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>VL</given-names></name><name><surname>Skevington</surname><given-names>SM</given-names></name><name><surname>Osborn</surname><given-names>M</given-names></name></person-group><article-title>Assessing the properties of the WHOQOL-Pain: quality of life of chronic low
back pain patients during treatment.</article-title><source>Clin J Pain.</source><year>2010</year><volume>26</volume><issue>7</issue><fpage>583</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1097/AJP.0b013e3181e11369</pub-id><pub-id pub-id-type="pmid">20639736</pub-id></element-citation></ref><ref id="A1845R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>J</given-names></name><name><surname>Esmail</surname><given-names>R</given-names></name><name><surname>Karjalainen</surname><given-names>K</given-names></name><name><surname>Malmivaara</surname><given-names>A</given-names></name><name><surname>Irvin</surname><given-names>E</given-names></name><name><surname>Bombardier</surname><given-names>C</given-names></name></person-group><article-title>Withdrawn: Multidisciplinary bio-psycho-social rehabilitation for chronic
low-back pain.</article-title><source>Cochrane Database Syst Rev.</source><year>2006</year><volume>18</volume><issue>2</issue><fpage>CD000963</fpage></element-citation></ref><ref id="A1845R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brin</surname><given-names>MF</given-names></name></person-group><article-title>Basic and clinical aspects of BOTOX.</article-title><source>Toxicon.</source><year>2009</year><volume>54</volume><issue>5</issue><fpage>676</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2009.03.021</pub-id><pub-id pub-id-type="pmid">19341758</pub-id></element-citation></ref><ref id="A1845R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankovic</surname><given-names>J</given-names></name></person-group><article-title>Botulinum toxin therapy for cervical dystonia.</article-title><source>Neurotox Res.</source><year>2006</year><volume>9</volume><issue>2-3</issue><fpage>145</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/BF03033933</pub-id><pub-id pub-id-type="pmid">16785112</pub-id></element-citation></ref><ref id="A1845R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quagliato</surname><given-names>EM</given-names></name><name><surname>Carelli</surname><given-names>EF</given-names></name><name><surname>Viana</surname><given-names>MA</given-names></name></person-group><article-title>A prospective, randomized, double-blind study comparing the efficacy and
safety of type a botulinum toxins botox and prosigne in the treatment of cervical
dystonia.</article-title><source>Clin Neuropharmacol.</source><year>2010</year><volume>33</volume><issue>1</issue><fpage>22</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19959960</pub-id></element-citation></ref><ref id="A1845R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brin</surname><given-names>MF</given-names></name><name><surname>Lyons</surname><given-names>KE</given-names></name><name><surname>Doucette</surname><given-names>J</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Caviness</surname><given-names>JN</given-names></name><name><surname>Comella</surname><given-names>CL</given-names></name><etal>et al.</etal></person-group><article-title>A randomized, double masked, controlled trial of botulinum toxin type A in
essential hand tremor.</article-title><source>Neurology.</source><year>2001</year><volume>56</volume><issue>11</issue><fpage>1523</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/WNL.56.11.1523</pub-id><pub-id pub-id-type="pmid">11402109</pub-id></element-citation></ref><ref id="A1845R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheffield</surname><given-names>JK</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name></person-group><article-title>Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and
other symptoms associated with Parkinson's disease.</article-title><source>Expert Rev Neurother.</source><year>2007</year><volume>7</volume><issue>6</issue><fpage>637</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1586/14737175.7.6.637</pub-id><pub-id pub-id-type="pmid">17563247</pub-id></element-citation></ref><ref id="A1845R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molenaers</surname><given-names>G</given-names></name><name><surname>Schorkhuber</surname><given-names>V</given-names></name><name><surname>Fagard</surname><given-names>K</given-names></name><name><surname>Van Campenhout</surname><given-names>A</given-names></name><name><surname>De Cat</surname><given-names>J</given-names></name><name><surname>Pauwels</surname><given-names>P</given-names></name><etal>et al.</etal></person-group><article-title>Long-term use of botulinum toxin type A in children with cerebral palsy:
treatment consistency.</article-title><source>Eur J Paediatr Neurol.</source><year>2009</year><volume>13</volume><issue>5</issue><fpage>421</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2008.07.008</pub-id><pub-id pub-id-type="pmid">18977158</pub-id></element-citation></ref><ref id="A1845R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>LC</given-names></name><name><surname>Wong</surname><given-names>SW</given-names></name><name><surname>Hamid</surname><given-names>HA</given-names></name></person-group><article-title>Treatment of drooling in children with cerebral palsy using ultrasound
guided intraglandular injections of Botulinum Toxin A.</article-title><source>J Pediatr Neurol.</source><year>2009</year><volume>7</volume><issue>2</issue><fpage>141</fpage><lpage>5</lpage></element-citation></ref><ref id="A1845R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifart</surname><given-names>A</given-names></name><name><surname>Unger</surname><given-names>M</given-names></name><name><surname>Burger</surname><given-names>M</given-names></name></person-group><article-title>Functional electrical stimulation to lower limb muscles after botox in
children with cerebral palsy.</article-title><source>Pediatr Phys Ther.</source><year>2010</year><volume>22</volume><issue>2</issue><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1097/PEP.0b013e3181dbd806</pub-id><pub-id pub-id-type="pmid">20473105</pub-id></element-citation></ref><ref id="A1845R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elovic</surname><given-names>EP</given-names></name><name><surname>Brashear</surname><given-names>A</given-names></name><name><surname>Kaelin</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Millis</surname><given-names>SR</given-names></name><name><surname>Barron</surname><given-names>R</given-names></name><etal>et al.</etal></person-group><article-title>Repeated treatments with botulinum toxin type a produce sustained decreases
in the limitations associated with focal upper limb poststroke spasticity for caregivers
and patients.</article-title><source>Arch Phys Med Rehabil.</source><year>2008</year><volume>89</volume><issue>5</issue><fpage>799</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.apmr.2008.01.007</pub-id><pub-id pub-id-type="pmid">18452724</pub-id></element-citation></ref><ref id="A1845R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosales</surname><given-names>RL</given-names></name><name><surname>Chua-Yap</surname><given-names>AS</given-names></name></person-group><article-title>Evidence-based systematic review on the efficacy and safety of botulinum
toxin-A therapy in post-stroke spasticity.</article-title><source>J Neural Transm.</source><year>2008</year><volume>115</volume><issue>4</issue><fpage>617</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s00702-007-0869-3</pub-id><pub-id pub-id-type="pmid">18322637</pub-id></element-citation></ref><ref id="A1845R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jost</surname><given-names>WH</given-names></name></person-group><article-title>Botulinum toxin in multiple sclerosis.</article-title><source>J Neurol.</source><year>2006</year><volume>253</volume><issue>Suppl 1</issue><fpage>I16</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s00415-006-1104-0</pub-id><pub-id pub-id-type="pmid">16477480</pub-id></element-citation></ref><ref id="A1845R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehnert</surname><given-names>U</given-names></name><name><surname>Birzele</surname><given-names>J</given-names></name><name><surname>Reuter</surname><given-names>K</given-names></name><name><surname>Schurch</surname><given-names>B</given-names></name></person-group><article-title>The effect of botulinum toxin type a on overactive bladder symptoms in
patients with multiple sclerosis: a pilot study.</article-title><source>J Urol.</source><year>2010</year><volume>184</volume><issue>3</issue><fpage>1011</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2010.05.035</pub-id><pub-id pub-id-type="pmid">20643431</pub-id></element-citation></ref><ref id="A1845R19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schapiro</surname><given-names>RT</given-names></name></person-group><source>Managing the symptoms of multiple sclerosis.</source><year>2007</year><edition>5th ed</edition><publisher-loc>New York</publisher-loc><publisher-name>Demos Medical Pub</publisher-name></element-citation></ref><ref id="A1845R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahman</surname><given-names>J</given-names></name></person-group><article-title>Botulinum toxin treatment of low back pain and
fibromyalgia.</article-title><source>Toxicon.</source><year>2008</year><volume>51</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2008.04.146</pub-id></element-citation></ref><ref id="A1845R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>L</given-names></name><name><surname>Clapp</surname><given-names>L</given-names></name><name><surname>Erickson</surname><given-names>M</given-names></name><name><surname>Jabbari</surname><given-names>B</given-names></name></person-group><article-title>Botulinum toxin A and chronic low back pain: a randomized, double-blind
study.</article-title><source>Neurology.</source><year>2001</year><volume>56</volume><issue>10</issue><fpage>1290</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1212/WNL.56.10.1290</pub-id><pub-id pub-id-type="pmid">11376175</pub-id></element-citation></ref><ref id="A1845R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabbari</surname><given-names>B</given-names></name></person-group><article-title>Treatment of chronic low back pain with botulinum
neurotoxins.</article-title><source>Curr Pain Headache Rep.</source><year>2007</year><volume>11</volume><issue>5</issue><fpage>352</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s11916-007-0217-1</pub-id><pub-id pub-id-type="pmid">17894925</pub-id></element-citation></ref><ref id="A1845R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarajan</surname><given-names>V</given-names></name><name><surname>Al-Shubaili</surname><given-names>A</given-names></name><name><surname>Ayad</surname><given-names>YM</given-names></name><name><surname>Alexander</surname><given-names>J</given-names></name><name><surname>Al-Ramezi</surname><given-names>K</given-names></name></person-group><article-title>Low back ache treatment with botulinum neurotoxin type A. Local experience
in Kuwait.</article-title><source>Med Princ Pract.</source><year>2007</year><volume>16</volume><issue>3</issue><fpage>181</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1159/000100387</pub-id><pub-id pub-id-type="pmid">17409751</pub-id></element-citation></ref><ref id="A1845R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ney</surname><given-names>JP</given-names></name><name><surname>Difazio</surname><given-names>M</given-names></name><name><surname>Sichani</surname><given-names>A</given-names></name><name><surname>Monacci</surname><given-names>W</given-names></name><name><surname>Foster</surname><given-names>L</given-names></name><name><surname>Jabbari</surname><given-names>B</given-names></name></person-group><article-title>Treatment of chronic low back pain with successive injections of botulinum
toxin a over 6 months: a prospective trial of 60 patients.</article-title><source>Clin J Pain.</source><year>2006</year><volume>22</volume><issue>4</issue><fpage>363</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/01.ajp.0000174267.06993.3f</pub-id><pub-id pub-id-type="pmid">16691090</pub-id></element-citation></ref><ref id="A1845R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>DD</given-names></name><name><surname>McGrath</surname><given-names>PA</given-names></name><name><surname>Rafii</surname><given-names>A</given-names></name><name><surname>Buckingham</surname><given-names>B</given-names></name></person-group><article-title>The validation of visual analogue scales as ratio scale measures for
chronic and experimental pain.</article-title><source>Pain.</source><year>1983</year><volume>17</volume><issue>1</issue><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(83)90126-4</pub-id><pub-id pub-id-type="pmid">6226917</pub-id></element-citation></ref><ref id="A1845R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairbank</surname><given-names>JC</given-names></name><name><surname>Couper</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>JB</given-names></name><name><surname>O'Brien</surname><given-names>JP</given-names></name></person-group><article-title>The Oswestry low back pain disability questionnaire.</article-title><source>Physiotherapy.</source><year>1980</year><volume>66</volume><issue>8</issue><fpage>271</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">6450426</pub-id></element-citation></ref><ref id="A1845R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>DD</given-names></name><name><surname>Bush</surname><given-names>FM</given-names></name><name><surname>Long</surname><given-names>S</given-names></name><name><surname>Harkins</surname><given-names>SW</given-names></name></person-group><article-title>A comparison of pain measurement characteristics of mechanical visual
analogue and simple numerical rating scales.</article-title><source>Pain.</source><year>1994</year><volume>56</volume><issue>2</issue><fpage>217</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(94)90097-3</pub-id><pub-id pub-id-type="pmid">8008411</pub-id></element-citation></ref><ref id="A1845R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabbari</surname><given-names>B</given-names></name><name><surname>Ney</surname><given-names>J</given-names></name><name><surname>Sichani</surname><given-names>A</given-names></name><name><surname>Monacci</surname><given-names>W</given-names></name><name><surname>Foster</surname><given-names>L</given-names></name><name><surname>Difazio</surname><given-names>M</given-names></name></person-group><article-title>Treatment of refractory, chronic low back pain with botulinum neurotoxin A:
an open-label, pilot study.</article-title><source>Pain Med.</source><year>2006</year><volume>7</volume><issue>3</issue><fpage>260</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4637.2006.00147.x</pub-id><pub-id pub-id-type="pmid">16712627</pub-id></element-citation></ref><ref id="A1845R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subin</surname><given-names>B</given-names></name><name><surname>Saleemi</surname><given-names>S</given-names></name><name><surname>Morgan</surname><given-names>G</given-names></name><name><surname>Zavisca</surname><given-names>F</given-names></name><name><surname>Cork</surname><given-names>R</given-names></name></person-group><article-title>Treatment of Chronic Low Back Pain by Local Injection of Botulinum
Toxin-A.</article-title><source>Internet J Pain, Symptom Control and Palliat Care.</source><year>2003</year><volume>2</volume><issue>2</issue></element-citation></ref><ref id="A1845R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dressler</surname><given-names>D</given-names></name></person-group><article-title>Botulinum toxin mechanisms of action.</article-title><source>Suppl Clin Neurophysiol.</source><year>2004</year><volume>57</volume><fpage>159</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S1567-424X(09)70353-8</pub-id><pub-id pub-id-type="pmid">16106616</pub-id></element-citation></ref><ref id="A1845R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranoux</surname><given-names>D</given-names></name><name><surname>Attal</surname><given-names>N</given-names></name><name><surname>Morain</surname><given-names>F</given-names></name><name><surname>Bouhassira</surname><given-names>D</given-names></name></person-group><article-title>Botulinum toxin type A induces direct analgesic effects in chronic
neuropathic pain.</article-title><source>Ann Neurol.</source><year>2008</year><volume>64</volume><issue>3</issue><fpage>274</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1002/ana.21427</pub-id><pub-id pub-id-type="pmid">18546285</pub-id></element-citation></ref><ref id="A1845R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>MJ</given-names></name><name><surname>Purkiss</surname><given-names>JR</given-names></name><name><surname>Foster</surname><given-names>KA</given-names></name></person-group><article-title>Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium
botulinum neurotoxins.</article-title><source>Toxicon.</source><year>2000</year><volume>38</volume><issue>2</issue><fpage>245</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(99)00153-1</pub-id><pub-id pub-id-type="pmid">10665805</pub-id></element-citation></ref></ref-list></back></article>